Loading patent…
AssigneesArch Development Corporation, UR Labs, Inc.
InventorsJoseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
Estimating the term…
A method for preventing or treating opioid induced side effects including dysphoria, pruritus and urinary retention and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered by the route selected from the group consisting of intravenous, intramuscular, transmucosal, transdermal, and oral administration, preferably administered orally in an enterically coated form.
A method for preventing opioid induced side effects comprising administering a quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid, the side effect selected from the group consisting of dysphoria, pruritus, and urinary retention.
A method for treating opioid induced side effects comprising administering a quaternary derivative of noroxymorphone to a patient subsequent to the administration of an opioid, the side effect selected from the group consisting of dysphoria, pruritus, and urinary retention.
A method for preventing nonopioid induced gastrointestinal dysfunction comprising administering a quaternary derivative of noroxymorphone to a patient prior to the onset of the gastrointestinal dysfunction.
A method for treating nonopioid induced gastrointestinal dysfunction comprising administering a quaternary derivative of noroxymorphone to a patient after the onset of the gastrointestinal dysfunction.
A method for preventing opioid induced dysphoria comprising administering a quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid.
A method for treating opioid induced dysphoria comprising administering a quaternary derivative of noroxymorphone to a patient subsequent to the administration of an opioid.
Dependencies are inferred from the claim text.